Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Glycopyrronium bromide 0.1% topical solution
1312000G0AAAFAF
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | 4 |
|
Glycopyrronium bromide 1% cream
1312000G0AAAMAM
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | 4 |
|
Glycopyrronium bromide 1.5mg/5ml oral solution
0102000L0AABLBL
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | 3 |
|
Glycopyrronium bromide 2mg capsules
0102000L0AABKBK
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | 3 |
|
Glycopyrronium bromide 750micrograms/5ml oral liquid
0102000L0AAAFAF
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | 3 |
|
Glycopyrronium bromide 0.5% in Cetomacrogol crm (Formula A)
1312000G0AAAZAZ
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | 2 |
|
Glycopyrronium bromide 1% in Aqueous cream
1312000G0AAAVAV
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | 2 |
|
Glycopyrronium bromide 2% in Aqueous cream
1312000G0AAAUAU
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | 2 |
|
Glycopyrronium bromide 2% in Generic Unguentum M cream
1312000G0AABFBF
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | 2 |
|
Glycopyrronium bromide 0.5% in Generic Unguentum M cream
1312000G0AABIBI
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | 1 |
|
Glycopyrronium bromide 2% cream
1312000G0AAANAN
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | 1 |
|
Glycopyrronium bromide 4% cream
1312000G0AAATAT
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | 1 |
|
Glycopyrronium bromide 4mg/5ml oral solution
0102000L0AAAVAV
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | 1 |
|
Glycopyrronium bromide powder for solution for iontophoresis
1312000G0AAAAAA
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | 1 |
|
Glycopyrronium bromide 0.05% cream
1312000G0AAAYAY
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | No data available |
|
Glycopyrronium bromide 0.2% in Aqueous cream
1312000G0AABDBD
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | No data available |
|
Glycopyrronium bromide 0.5% in Aqueous cream
1312000G0AAAXAX
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | No data available |
|
Glycopyrronium bromide 0.5% solution
1312000G0AAAIAI
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | No data available |
|
Glycopyrronium bromide 1.25mg/5ml oral liquid
0102000L0AAALAL
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | No data available |
|
Glycopyrronium bromide 1.3mg/5ml oral suspension
0102000L0AABJBJ
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | No data available |
|
Glycopyrronium bromide 1.8mg/5ml oral liquid
0102000L0AAASAS
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | No data available |
|
Glycopyrronium bromide 1% in Cetomacrogol cream (Formula A)
1312000G0AABABA
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | No data available |
|
Glycopyrronium bromide 1% in Generic Unguentum M cream
1312000G0AABBBB
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | No data available |
|
Glycopyrronium bromide 1% in White soft paraffin
1312000G0AABEBE
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | No data available |
|
Glycopyrronium bromide 1% solution
1312000G0AAADAD
|
Glycopyrronium (Topical) | Glycopyrronium bromide | Skin | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.